688139 Qingdao Haier Biomedical Co., Ltd.
- 39.50
- +0.02+0.05%
Qingdao Haier Biomedical Co., Ltd. News
Shareholder Qi Jun Investment of Qingdao Haier Biomedical Co., Ltd. (688139.SH) has cumulatively reduced its shareholding in the company by 1.29%.
Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that on June 11, 2024, the company received a shareholder's notice from Ningbo...
Qingdao Haier Biomedical Co., Ltd. (688139.SH) did not repurchase its shares in May.
On May 2024, Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that the company did not repurchase shares through Shanghai Stock Exchange trading system in a centralized bidding trading manner. As of May 31, 2024, the company has repurchased a cumulative total of 815,617 shares of the company through Shanghai Stock Exchange trading system in a centralized bidding trading manner, accounting for 0.26% of the total share capital of 317,952,508 shares, with the highest repurchase price of 32.31 yuan/share, the lowest repurchase price of 27.40 yuan/share, and the total fund paid was 25,654,978.4 yuan.
Haier Biotech (688139.SH) will distribute the 2023 cash dividend of 0.515 yuan per share on June 6
Haier Biotech (688139.SH) announced that the company will release the 2023 annual report on June 6, 2024...
Haier Biotech (688139): Acquired Shanghai Yuanshi to improve analytical instrument layout
Key investment events: On May 23, 2024, Haier Biotech announced that it plans to acquire a holding of Shanghai Yuanshi Instrument Co., Ltd. (hereinafter referred to as “Shanghai Yuanshi”) through an agreement transfer, holding 70% of Shanghai Yuanshi's shares. Shanghai
Haier Biotech (688139) Commentary on important matters: Proposed acquisition of Shanghai Yuanshi officially enters the scientific analytical instrument circuit
Matters: Recently, the company announced that it plans to acquire a holding of Shanghai Yuanshi Instrument Co., Ltd. (Shanghai Yuanshi) through an agreed transfer and hold 70% of Shanghai Yuanshi's shares. Comment: Shanghai Yuanshi is deeply involved in the field of industrial scientific analytical instruments. Shanghai Yuanshi was founded
Haier Biotech (688139): Plans to acquire Shanghai Yuanshi to enter the scientific analytical instrument circuit to expand the category and continue to implement the growth logic
Incident: The company plans to acquire control of Shanghai Yuanshi. On May 23, 2024, the company announced its intention to acquire Shanghai Yuanshi through an agreed transfer and hold 70% of Shanghai Yuanshi's shares. The subject of the acquisition is a scientific analyzer from Shanghai Yuanshi
Pharmaceutical stocks changed partially. Kyodo Pharmaceutical rose more than 16%, while Qianyuan Pharmaceutical, Yiduoli, Sannuo Biotech, Haier Biotech, and Kazanlian followed suit.
Pharmaceutical stocks changed partially. Kyodo Pharmaceutical rose more than 16%, while Qianyuan Pharmaceutical, Yiduoli, Sannuo Biotech, Haier Biotech, and Kazanlian followed suit.
Haier Biotech (688139): Officially enters the scientific analytical instrument circuit to further enrich non-storage products
Proposed merger and acquisition of Shanghai Yuanshi, and the company officially entered the analytical instrument market event: On May 23, Haier Biotech announced that it plans to achieve a holding acquisition of Shanghai Yuanshi Instrument Co., Ltd. (hereinafter referred to as “Shanghai Yuanshi”) through an agreed transfer, holding Shanghai
Express News | Haier Biotech: Qijun Investment plans to reduce its holdings by no more than 1%.
Express News | Haier Biotech: Qijun Investment plans to reduce holdings by no more than 1.6%
Haier Biotech (688139.SH): Repurchase a total of 815,600 company shares
Gelonghui, May 6, 丨 Haier Biotech (688139.SH) announced that as of April 30, 2024, the company had repurchased a total of 815,617 shares through the Shanghai Stock Exchange trading system, accounting for 0.26% of the company's total share capital of 317,952,508 shares. The highest price of the repurchase transaction was RMB 32.31 per share, the lowest price was RMB 27.40 per share, and the total amount of capital paid was RMB 25,654,978.48 (excluding transaction fees).
Haier Biotech (688139) 2024 Quarterly Report Review: The main business showed a recovery trend, and performance improved month-on-month
Matters: The company released financial report. In 24Q1, the company achieved operating income of 687 million yuan, up 0.04% year on year, up 51.12% month on month; net profit to mother was 138 million yuan, up 0.06% year on year, up 1 month on month
Haier Biotech (688139): Q1 performance exceeds expectations, Q2 inflection point is approaching
[Key investment events: On April 26, 2024, the company released its report for the first quarter of 2024. 2024Q1 revenue of 687 million yuan (+0.04%, same ratio in parentheses, same below), net profit of 1.3 million yuan to mother
Haier Biotech (688139) Comment: The inflection point of performance is clear, and the layout of the new industry continues to improve
Incident Overview The company released its 2024 quarterly report. 2024Q1 achieved revenue of 687 million yuan, up 0.04% year on year and 51% month on month; net profit to mother was 138 million yuan, up 0.06% year on year.
Haier Biotech (688139): Performance improved in the first quarter and is expected to return to growth
Event: The company released its report for the first quarter of 2024. In the first quarter of 2024, it achieved operating income of 687 million yuan (+0.04%), net profit to mother of 138 million yuan (+0.06%), less non-net profit1
China Post Securities released a research report on April 26 stating that it gave Haier Biotech (688139.SH) a purchase rating. The main reasons for the rating include: 1) 2024Q1 achieved positive year-on-year growth in performance, with rapid month-on-mon
China Post Securities released a research report on April 26 stating that it gave Haier Biotech (688139.SH) a purchase rating. The main reasons for the rating include: 1) 2024Q1 achieved positive year-on-year growth in performance, with rapid month-on-month growth; 2) continuous improvement of non-storage products to support rapid growth in new industries; 3) strong infrastructure and recovery to promote the integrated development of the life science and medical innovation sector; 4) domestic market sinking, and the backlog of foreign projects is expected to gradually transform. (Mainichi Keizai Shimbun)
Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Qingdao Haier BiomedicalLtd (SHSE:688139) has had a great run on the share market with its stock up by a significant 22% over the last month. Given that stock prices are usually aligned with a compa
Haier Biotech (688139.SH): Net profit of 138 million yuan in the first quarter increased 0.06% year over year
On April 25, GLONGHUI (688139.SH) released its first quarter report. Operating revenue was 687 million yuan, up 0.04% year on year, net profit of 138 million yuan, up 0.06% year on year, after deducting non-net profit of 130 million yuan, up 6.64% year on year, with basic earnings of 0.44 yuan per share.
Haier Biotech (688139): The inflection point has reached the second and the growth curve is clear
Key investment points Financial performance: Performance has been drastically recovered. The inflection point has reached 2024Q1, the company achieved revenue of 687 million yuan. Under high base pressure, the year-on-year increase was 0.04%, and the month-on-month increase was 51%, reaching the highest point in nearly 5 quarters
Haier Biotech (688139): 24Q1 performance resumed growth and embraced new quality productivity to expand business layout
Incident: The company released its 2024 quarterly report, and the results slightly exceeded expectations. In 24Q1, the company achieved operating income of 687 million yuan, an increase of 0.04% year on year; net profit to mother was 138 million yuan, up 0.06% year on year, month on month
Analysis
Price Target
No Data
